Skip to main content
. 2012 Jan 12;106(4):748–755. doi: 10.1038/bjc.2011.587

Figure 3.

Figure 3

Progression-free survival (PFS) of metastatic colorectal cancer patients receiving first-line and second-line chemotherapy by AURKA-CN and KRAS mutation status. (A) PFS on first-line chemotherapy by AURKA-CN; (B) PFS on first-line chemotherapy by AURKA-CN and KRAS mutation status; (C) PFS on second-line chemotherapy by AURKA-CN; and (D) PFS on second-line chemotherapy by AURKA-CN and KRAS mutation status.